(Length of Discussion: 16 min)

Dr. Tom Keane discusses the rapidly changing landscape in advanced bladder cancer with the introduction of immune checkpoint inhibitors. To begin his discussion he references a presentation by Thomas Powles, MD from the 2018 ASCO GU meeting where Dr. Powles provided an overview of immune checkpoint inhibitors in urothelial carcinoma at the current time and Dr. Powles's input on which one to use.

The second presentation Tom highlights is the Two-year Follow-up: 3 KEYNOTE-045 Trial of Pembrolizumab vs Investigator’s Choice Chemotherapy in Recurrent, Advanced Urothelial Cancer (UC) presentation by Dr. Joaquim Bellmunt who presented updated results after 2 years of follow-up where pembrolizumab was approved for the treatment of locally advanced or metastatic UC that has progressed during or after a platinum-containing regimen. The last presentation he highlights is Lessons Learned From New Guidelines and How They Have Changed Management of Muscle-Invasive Bladder Cancer by  Dr. Jeff Holzbeierlein who presented the new muscle-invasive bladder cancer (MIBC) guidelines all of which were given A, B or C grades. Tom overviews some key guidelines recommendations for the consensus, including diagnosis, MIBC management, bladder sparing therapy for MIBC, and primary radiation therapy.

Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS

Related Content:

Immune Checkpoint Inhibitors: Which One and Why?

Two-year Follow-up: 3 KEYNOTE-045 Trial of Pembrolizumab vs Investigator’s Choice Chemotherapy in Recurrent, Advanced Urothelial Cancer

Lessons Learned From New Guidelines and How They Have Changed Management of Muscle-Invasive Bladder Cancer